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Abstract 
 
Precision medicine is an emerging paradigm that aims at maximizing the benefits and minimizing the 
adverse effects of drugs. Realistic mechanistic models are needed to understand and limit 
heterogeneity in drug responses. While pharmacokinetic models describe in detail a drug’s 
absorption and metabolism, they generally do not account for individual variations in response to 
environmental influences, in addition to genetic variation. For instance, the human gut microbiota 
metabolizes drugs and is modulated by diet, and it exhibits significant variation among individuals. 
However, the influence of the gut microbiota on drug failure or drug side effects is under-
researched. Here, we review recent advances in computational modeling approaches that could 
contribute to a better, mechanism-based understanding of drug-microbiota-diet interactions and 
their contribution to individual drug responses. By integrating systems biology and quantitative 
systems pharmacology with microbiology and nutrition, the conceptually and technologically 
demand for novel approaches could be met to enable the study of individual variability, thereby 
providing breakthrough support for progress in precision medicine. 
 
Highlights   
• The response to drug treatment is highly variable among individuals. 
• Pharmacokinetic modeling has been used to improve and accelerate drug discovery but 
it does not account for a person’s diet and gut microbiota. 
• Here, we propose an approach combining constraint-based and pharmacokinetic 
modeling to capture also dietary and gut microbial metabolism. 
• Such integrated models will enable the individual-specific prediction of drug response. 
 
Introduction 
The effect of drug treatment varies significantly among individuals, and genetic differences alone are 
insufficient to explain the observed inter-individual differences in drug response [1]. Human gut 
microbes metabolize many drugs [2]; however, their contribution to an individual’s drug response 
and safety is poorly understood. Diet also modulates the microbiota composition and biochemical 
functions and alters drug bioavailability. Recent technological advances have led to a greater 
understanding of the diversity and abundance of gut microbial species. Consequently, research focus 
is shifting toward exploring the effects of a person’s microbiota on metabolism and drug 
metabolism. Accordingly, constraint-based computational models have been applied to investigate 
how the gut microbiota can modulate the human metabolic phenotype [3]. In parallel, 
pharmacokinetic models are used to predict drug responses at the whole-body level [4]. 
Despite these advances, computational modeling efforts have yet not considered the joint effects of 
human gut microbiota metabolism, drug metabolism and diet. Consequently, neither the 
pharmaceutical industry nor academic researchers can properly exploit the increasing knowledge on 
the human gut microbiota as well as microbiota- and diet-related interpersonal variability for drug 
development and clinical trial design. The application of statistical methods to genomic or clinical 
data in pharmacogenomics has been of limited use for patient and therapeutic stratification [5] and 
does not provide a mechanistic system-level understanding of the targeted biological systems. 
Another limitation of pharmacogenomics is its failure to integrate exogenous factors that alter drug 
bioavailability, such as the human gut microbiota or diet [6]. 
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Human and microbial drug metabolism 
 
Individual drug response. Variations in individual treatment responses pose a major challenge to 
health professionals and patients as well as to drug development and clinical trial design [7]. Front-
line physicians must therefore adapt a pragmatic or empirical prescription decision tree until an 
effective therapy for each patient is identified. Furthermore, the adverse drug reactions that may 
ensue are ranked among the top 10 causes of morbidity and mortality in the developed world [8]. 
Certain adverse effects are related to the production of toxic drug metabolites [9], and both the 
duration and extent of pharmacological action are related to the rate of drug metabolism [10]. 
Pharmacogenomic studies have greatly improved our understanding of individual variations in drug 
metabolism caused by genetic individuality [11]. However, these studies cannot explain the large 
observed individual variability in drug response as they only focus on the genetic variability of drug-
metabolism related genes. Consequently, variation in a person’s physiology, such as gender, 
ethnicity, body mass index, should be considered. Moreover, environmental factors, such as diet, 
gut microbiota composition, exercise, and stress, can modulate a person's metabolic phenotype and 
drug metabolism. As these factors can significantly alter drug efficacy and safety profiles [12], they 
must be accounted for in drug development and treatment.  
 
Gut microbial drug metabolism. The human gut microbiota is a metabolically active community of 
10 to 100 trillion commensal, pathogenic, and symbiotic organisms composed of 500-1000 species 
and including two to four million different genes [13, 14]. The gut microbiota contributes to the 
essential functions of the human host, such as food digestion, essential amino acids and vitamin 
synthesis, pathogen protection, and host immune system maturation [15]. The gut microbiota has 
also emerged as a significant factor influencing drug response [2]. Gut microbes affect drug 
efficiency both directly and indirectly. In turn, exposure to antibiotics and host-targeted drugs 
induced changes in gut microbiota gene expression across several phyla [16]. This xenobiotic 
modulation of microbial gene expression varies between human individuals suggesting a gut 
microbiota-dependent personalized drug response [16]. At least 30 host-targeted drugs are directly 
affected by gut microbial activity [17, 18] (Figure 1), yet mechanistic insight in the effects on drug 
efficiency and safety is often lacking [19]. 
 
Direct microbial effects on drugs include chemically modifying drug structures, binding to drugs, and 
degrading drugs [17, 20]. The gut microbiome encodes enzymes that perform drug transformations, 
including reduction, acetylation, deacetylation, and demethylation [17]. In certain cases, these 
transformations result in the desired conversion of a prodrug to an active drug. For example, the 
prodrug sulfasalazine, a treatment for inflammatory bowel disease, is cleaved into the active drug 5-
aminosalicylic acid by intestinal microbial azoreductases [17]. However, in other cases, the drug is 
inactivated or converted into a more toxic form (Figure 1). For example, the cardiac drug digoxin is 
inactivated by the cardiac glycoside reductase of Eggerthella lenta [21]. This undesirable inactivation 
can be reduced by increasing the amount of dietary arginine, demonstrating that dietary 
interventions can influence drug-microbiota interactions [21]. Only E. lenta strains carrying the 
“cardiac glycoside reductase” (cgr) operon carry out this biotransformation. The abundance of 
cardiac glycoside reductase in stool samples has been shown to predict digoxin inactivation and the 
resulting reduction in drug activity [21, 22]. This example clearly demonstrates that genomic and 
transcriptomic analyses of the gut microbiota can be useful for predicting drug responses [12, 16].  
 
Additionally, gut microbes can indirectly affect the drug response and toxicity by the production of 
microbial metabolites. One example is the gut microbial production of p-cresol that competes with 
the acetaminophen for sulfonation by a liver enzyme and thus contributes to drug toxicity in certain 
individuals [10]. To date, few mechanistic insights have been provided for the effects of drug-
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microbiota interactions, including drug efficacy and safety, and the species capable of drug 
transformations are largely unknown [17]. Moreover, the gut microbiota is characterized by 
functional redundancy, i.e., the same functions can be performed by multiple bacteria that may be 
either closely or distantly related [23]. This redundancy also extends to drug-metabolizing genes in 
multiple species across phyla. Hence, a microbiota-wide systematic approach to exploiting and 
characterizing the capabilities of the gut microbiota to modulate drug metabolism is urgently 
required. 
 
Computational modeling approaches 
 
Pharmacokinetic models quantitatively describe the absorption, distribution, metabolism and 
elimination (ADME) of a drug to predict the time course of a drug’s concentration in the body [24, 
25]. In particular, physiologically based pharmacokinetic (PBPK) models, which compose the core of 
quantitative systems pharmacology [26, 27], describe whole-body drug kinetics by using ordinary 
differential equations and an organ compartment structure [28, 29] (Figure 2). These models contain 
system-specific and drug-specific parameters. The system-specific parameters include blood flow, 
organ volumes, enzyme and transporter expression, and plasma protein concentrations [30]. The 
drug-specific parameters include intrinsic clearances, volume of distribution, solubility and 
physicochemical parameters, tissue partitioning, plasma protein binding affinity, and membrane 
permeability [30]. The drug-dependent parameters allow for the mechanistic extrapolation of 
human pharmacokinetics from in vitro and in silico data via a “bottom-up” approach [31]. Whole-
body PBPK models have been published for at least 50 drugs [32-34], including 32 with an advanced 
compartment absorption and transit model (ACAT). The ACAT model [35] was based on a CAT model 
[36], which did not consider the dissolution of solid particles. The ACAT model considers nine 
gastrointestinal compartments, being the stomach, seven small intestinal segments, and the large 
intestine. It represents pH-dependent drug solubility, controlled release, drug absorption by the 
stomach and colon, metabolism in the gut or liver, degradation in the lumen, changes in absorption 
surface area, changes in drug transporter densities, and changes in efflux transporter densities. 
Drugs with low solubility or permeability may continue for absorption in the colon.  
 
PBPK models can be personalized by using system-specific parameters [37, 38]. Physiological 
parameters from specific populations include specific parameters for infants [39, 40], pregnant 
women [41, 42], and elderly people [43]. Despite the mechanistic details captured in PBPK models, 
they do not account for microbial metabolism. Moreover, they do not permit personalization based 
on dietary, microbial, or genetic data. Also, current PBPK models do not yet connect with the 
underlying network of genes, proteins, and biochemical reactions of human metabolism.  
 
In constraint-based reconstruction and analysis (COBRA), a metabolic reconstruction of an 
organism is assembled in a bottom-up manner on the basis of reaction stoichiometry and 
physicochemical properties obtained from genome annotations and biochemical and physiological 
data [44]. The conversion of a metabolic reconstruction into a condition-specific model includes the 
transformation of the biochemical reaction list into a mathematical format (a stoichiometric matrix, 
 ∈ ℝ
). It also requires the imposition of physico-chemical constraints (e.g., mass conservation) 
and designation of reactions for exchange of mass across systems [44]. The COBRA approach 
assumes that the modeled system is in a steady state (.  =




≡ 0). These constraints result in an 
underdetermined system of linear equations that includes fewer equations (mass-balances) than 
variables (reaction fluxes,  ∈ ℝ); thus, a polyhedral convex steady-state solution space contains all 
of the feasible steady-state solutions [44]. Adding further constraints (e.g., nutrient uptake rates, 
enzyme reaction rates) to the model can restrict the solution space to solutions that are biologically 
relevant under the given condition. Despite incomplete knowledge of many reaction rates, kinetic 
parameters, and metabolites and enzyme concentrations, COBRA permits the prediction of feasible 
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phenotypic properties of the modeled system. Comprehensive models of human metabolism 
(http://vmh.life) [45-47] exist. Additionally, we have created a stoichiometric reaction module, 
compatible with the human metabolic reconstruction [45] describing the metabolic transformation 
of the 18 most highly prescribed drugs, including statins, anti-hypertensions, immunosuppressants, 
and analgesics [48]. Such drug metabolic reactions are required to allow for the integration of the 
pharmacokinetic parameters with the COBRA models (see next section).    
 
The COBRA approach has been applied to numerous biomedical questions, including the phenotypic 
consequences of single nucleotide polymorphisms [49] and enzyme deficiencies [45, 50, 51], and 
predictions of side and off-target effects of drugs [52, 53]. With these resources in place, attention is 
now turning to their integration. 
 
Integration of PBPK and COBRA modeling 
To overcome the limitations associated with the steady-state assumption in COBRA models and the 
lack of biochemical details of PBPK models, hybrid COBRA-PBPK modeling approaches have been 
recently explored [54-56] (Figure 2). For instance, Krauss et al. [57] integrated a COBRA model of 
cellular liver metabolism, which consisted of 777 metabolites and 2539 reactions,  with a PBPK 
model of an human adult [55] to demonstrate an increase in predictive accuracy and mechanistic 
understanding for allopurinol treatment, ammonia detoxification, and paracetamol toxication. In a 
subsequent study, we combined seven copies of a COBRA model for a small intestinal epithelial cell 
[18], each consisting of 433 metabolites and 1318 reactions, with a physiology-based 
pharmacokinetic ACAT model [34]. We used this model to investigate the role of intestinal 
absorption on the bioavailability of levodopa, the predominant drug administered to patients with 
Parkinson’s disease. Investigating the different model parameters, we identified that plasma-level of 
levodopa were most sensitive to the gastric emptying rate and the loss due to microbial activity. For 
instance, Helicobacter pylori, which is frequently found in the stomach, binds levodopa and thereby 
reduces its bioavailability. 
 
Accounting for microbial metabolism and dietary information 
As a next step, more organs in PBPK models need to be represented at a molecular level. To this end, 
numerous cell- and tissue-specific metabolic reconstructions have been published [57-61]. To 
capture the gut microbial metabolism, we have recently published a most comprehensive collection 
of semi-manually curated metabolic reconstructions of 773 human gut microbes [62], named 
AGORA. This resource enables modeling of gut microbial communities and their interactions with 
the human host [63]. However, these microbial metabolic models do not yet capture xenobiotic 
metabolism [64], which will require the use using context-based comparative genomics techniques 
[65], to identify microbial enzymes known to modify drugs. The AGORA models can be combined 
into a microbiota community model [63] and parameterized using metagenomics data. This can be 
achieved by formulation of a microbial community biomass reaction summing all of the individual 
microbial biomass reaction fluxes. The stoichiometric coefficients of this community biomass 
reaction can be adapted on the basis of the relative microbial abundance reported in metagenomics 
data. The microbial community biomass reaction can be constrained such that its rate corresponds 
to the fecal excretion rate of an average human (e.g., once every 12-24 hours). Finally, the effect of 
diet as a modulator of human health and microbial composition has been studied using COBRA 
modeling [59, 63, 66, 67]. One excellent example has used the molecular composition of 24 defined 
food items for predicting their effect on human and microbial metabolism [66]. However, drug-diet 
interactions have not yet been computationally modeled using a COBRA modeling approach.  
 
Development of efficient computational approaches for hybrid COBRA-PBPK modeling  
To reliably and efficiently integrate PBPK and COBRA at large scale (Figure 2), the available hybrid 
modeling approaches needs to be refined. For instance, to ensure that the changes in calculated flux 
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vectors between two consecutive time steps respond as well-behaved functions (single-valued and 
Lipschitz continuous) of perturbations in the input data, the flux balance analysis problem can be 
regularized to ensure that it is a strictly convex optimization problem [68, 69] by minimizing the 
Euclidean distance between the current and next optimal flux vector. In addition, one could 
mathematically reformulate the problem by adapting techniques from discrete mechanics to pose 
the dynamic trajectory of an integrated pharmacokinetic and metabolic system as the optimal 
solution to a variational integration problem [70]. Moreover, a new quad-precision linear 
programming solver has been recently developed to allow for solving optimization problems ranging 
multiple scales [71], e.g., due to macro – and micronutrients in the diet. High-precision solvers are 
slower but guarantee return of an optimal flux vector to 16 digits of numerical precision, which is far 
beyond the precision of the biological measurements that are applied as modeling constraints or 
used for the non-integer stoichiometric coefficients (e.g., microbial abundance in the community 
biomass reaction).  
 
Pharmacokinetic simulations frequently focus on recurrent dynamics over a finite time interval, such 
as a regular 24 hour-dosing regime. In this case, time can be explicitly discretized, thus producing a 
set of coupled metabolic and pharmacokinetic equations with a variable for each time point. 
Additional constraints enforce the dynamic continuity of each feasible trajectory. The optimal 
dynamic time course can be obtained by solving an optimization problem over this set of possible 
trajectories. The key to the tractability of the optimization problem is to couple the pharmacokinetic 
model variables to linear kinetic reactions within the metabolic model. Therefore, the rate of each 
drug diffusion reaction in a metabolic model is a linear function of the drug concentration, and with 
a specified diffusion coefficient, a rate variable can be linearly coupled in a COBRA model to a 
concentration variable in a discrete dynamical system. This discretized system is high-dimensional 
but amenable to parallel computing because only the constraints enforcing dynamic continuity share 
variables representing different time points. 
 
Conclusion 
Despite the importance of diet and gut microbiota in drug metabolism, none of the current 
computational modeling approaches have integrated diet-microbiota-drug interactions. Hybrid 
COBRA-PBPK modeling leverages their individual strengths and overcomes some of their intrinsic 
weaknesses, e.g., steady-state assumption in COBRA and limited molecular details in PBPK modeling. 
Building on the growing knowledge of the gut microbiota and using cutting-edge computational 
modeling approaches will enable an unprecedented level of mechanistic understanding of 
personalized drug-microbiota-diet interactions. This new generation COBRA-PBPK models will 
combine a multi-level in silico description of human, microbial, and drug metabolism, which 
accurately represents the underlying network of genes, proteins, and biochemical reactions, as well 
as physiological processes and drug pharmacokinetics. Consequently, individual physiological 
parameters as well as exogenous factors that alter drug bioavailability can be used to generate 
personalized predictive models (Figure 3). More individualized treatment strategies, developed in 
silico yet based on individualized in vivo data, have great potential to contribute to personalized 
medicine and will enable in silico clinical trials and thereby directly contribute to the design of in vivo 
clinical trials, by enabling patient stratification to reduce the heterogeneity in treatment responses.  
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Figure Legend 
  
Figure 1:  Top. The human gut microbiota modulates drug metabolism in a direct and indirect 
manner. Particularly, the indirect mechanism relies computational modeling approaches for 
identification. Adapted from [20]. Bottom. Human and microbial metabolism of irinotecan, a 
chemotherapeutic drug that is frequently used for treating solid tumors. Approximately 35% of 
irinotecan-treated patients experience severe life-threatening toxicity, commonly manifesting as 
neutropenia and severe diarrhea, and they require unplanned dose reductions or the 
discontinuation of the therapy, thus prohibiting effective treatment [72]. The liver enzyme uridine-
diphosphate glucuronosyltransferase 1 (UDPGT1) catalyzes the inactivation of irinotecan. 
Polymorphisms in the corresponding gene have been reported [72] but are unlikely to be the only 
factor in the variability in drug toxicity. Inactivated (glucuronated) irinotecan is cleared via the 
enterohepatic route and may also be reabsorbed in the small intestine and excreted after passing 
the colon. Colonic microbial beta-glucuronidases can reactivate irinotecan by removing glucuronate, 
which can be used as a carbon source by certain microbes.  
 
Figure 2: Top: Schematic representation of a combined COBRA-PBPK multi-organ model. Each organ-
specific model can be derived from the generic human metabolic reconstruction (e.g., [45]) and 
consists of seven intra-cellular compartments (cytosol [c], nucleus, mitochondria, peroxisome, 
lysosome, endoplasmatic reticulum, and the golgi apparatus). The microbial models consist of two 
compartment each, i.e., cytosol and extra-organismal space and could be individualized using 
metagenomic data. The arterial blood compartment is illustrated with red lines, while the venous 
blood is represented with blue lines. Each organ contains an exchange compartment with the 
respective blood compartment ([ba] and [bv]). GI tract=gastro-intestinal tract. IEC=Intestinal 
epithelial cell. Bottom: Pseudoalgorithm for solving iteratively the hybrid PBPK and COBRA model. 
Step 0 is initialization, and steps 1-4 are iteratively repeated for a user-specified duration. Symbols: 
c, concentration of a drug metabolite; t, time point; vj, j
th
 reaction from the set of reactions Ω	that is 
present in both the PBPK and the COBRA model; v, flux vector containing a reaction rate for each 
reaction in the COBRA; model; lb, lower flux bound; and ub, upper flux bound. 
 
 
Figure 3: Overview of the proposed integrated computational approach for modeling host-diet-
microbe-drug interactions. Different types of data, including genomic, biochemical and physiological 
data, drug administration, and dietary information are integrated into a model consisting of 
genome-scale reconstructions of human and gut microbial metabolism with pharmacokinetic models 
of drug absorption and metabolism. Such an integrated, personalized model may yield individual-
specific predictions of drug metabolic pathway fluxes, end products of drug metabolism, and 
patients’ drug responses. Taken together, the proposed computational pipeline enables the 
simulation of clinical trials through patient-specific prediction of drug response, drug toxicity, the 
effects of dietary interventions. 
 
Table 1: List of resources and tools for building and simulating with metabolic and 
pharmacokinetic models. 
Biochemical data 
Kyoto Encyclopedia of Genes 
and Genomes (KEGG) 
http://www.genome.jp/kegg 
Virtual Metabolic Human https://vmh.life 
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Human Metabolome Database http://www.hmdb.ca 
Chemicalize by ChemAxon http://www.chemicalize.org/ 
Enzyme database BRENDA www.brenda-enzymes.org  
Drug metabolism 
DrugBank DB http://www.drugbank.ca/ 
Transformer http://bioinformatics.charite.de/transformer/ 
XmetDB http://www.xmetdb.org/ 
Protein 
UniProt www.uniprot.org  
The Human Protein Atlas www.proteinatlas.org 
Human Proteome Map http://www.humanproteomemap.org  
Drug information, pharmacokinetic, and pharmacogenetics  
Physiological parameters 
database for PBPK Modeling 
https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=204443 
Gene-drug interaction data https://cpicpgx.org/ 
Drug-drug information DIDB https://www.druginteractioninfo.org 
Drugs@FDA  
 
https://www.accessdata.fda.gov/scripts/cder/drugsatfda   
PharmGKB https://www.pharmgkb.org/index.jsp 
ClinVar http://www.ncbi.nlm.nih.gov/clinvar/ 
Side Effect Resource (SIDER) 
database 
http://sideeffects.embl.de/ 
VigiAccess http://www.vigiaccess.org/ 
EudraVigilance http://www.adrreports.eu/en/index.html 
European database of 
suspected adverse drug 
reaction reports 
www.adrreports.eu/ 
Clinical data 
ClinicalTrials.gov 
 
https://clinicaltrials.gov  
Clinical trial registry https://www.clinicaltrialsregister.eu/ 
Human Phenotype Ontology 
(HPO) 
http://compbio.charite.de/hpoweb/showterm?id=HP:0000118 
Online Mendelian Inheritance 
in Man (OMIM) 
http://www.omim.org/ 
Dietary information 
USDA food composition 
databases 
https://ndb.nal.usda.gov/ndb/ 
FooDB  http://foodb.ca/ 
Microbiome data repositories 
Human Microbiome Project 
DACC  
http://hmpdacc.org/resources/data_browser.php 
Integrative Human Microbiome 
Project (iHMP) 
http://ihmpdcc.org/ 
Human Pan-Microbe 
Communities (HPMC) database 
http://www.hpmcd.org/ 
EBI Metagenomics https://www.ebi.ac.uk/metagenomics/ 
Integrated reference catalog of http://meta.genomics.cn/meta/home  
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the human gut microbiome 
Computational model repository 
Virtual Metabolic Human http://vmh.life 
BIGG http://bigg.ucsd.edu/ 
BioModels Database https://www.ebi.ac.uk/biomodels-main/ 
Computational modeling tools and software 
COBRA toolbox https://github.com/opencobra 
GastroPlus
TM
 http://www.simulations-plus.com/software/gastroplus/ 
Simcyp https://www.certara.com/software/pbpk-modeling-and-
simulation/ 
PK-Sim http://www.systems-biology.com/products/pk-sim.html 
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• The response to drug treatment is highly variable among individuals. 
• Pharmacokinetic modeling has been used to improve and accelerate drug discovery but 
it does not account for a person’s diet and gut microbiota. 
• Here, we propose an approach combining constraint-based and pharmacokinetic 
modeling to capture also dietary and gut microbial metabolism. 
• Such integrated models will enable the individual-specific prediction of drug response. 
 
